Abstract 2103: Pharmacogenomic biomarkers of oncology drugs approved by the US FDA classified on the basis of BEST (Biomarkers, EndpointS, and other Tools) resource: systematic review - KIVIRID

Abstract 2103: Pharmacogenomic biomarkers of oncology drugs approved by the US FDA classified on the basis of BEST (Biomarkers, EndpointS, and other Tools) resource: systematic review

Authors: Tariq H. Alqurayshah,

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-2103

Source: Full article

Abstract

Abstract